Cytokinetics, Incorporated (CYTK)
| Market Cap | 10.07B +61.9% |
| Revenue (ttm) | 67.67M -21.1% |
| Net Income | -894.00M |
| EPS | -7.18 |
| Shares Out | 139.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,531,944 |
| Open | 73.51 |
| Previous Close | 73.77 |
| Day's Range | 72.34 - 74.65 |
| 52-Week Range | 47.22 - 88.31 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 109.90 (+51.69%) |
| Earnings Date | Aug 6, 2026 |
About CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h... [Read more]
Financial Performance
In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $109.9, which is an increase of 51.69% from the latest price.
News
Cytokinetics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
MYQORZO's launch is achieving strong momentum, with over 40% new-to-brand share and a goal of exceeding 50% by year-end, supported by physician education, improved market access, and rapid reimbursement. European expansion is underway, and pipeline progress includes upcoming regulatory milestones and a robust heart failure program.
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Cytokinetics Transcript: Citigroup’s Biopharma Back to School Summit 2026
ACACIA-HCM data has positioned MYQORZO for potential regulatory expansion to all HCM patients, with strong commercial momentum in OHCM and preparations for NHCM. The company is also advancing omecamtiv mecarbil in advanced heart failure, with a confirmatory trial designed to optimize outcomes.
Cytokinetics Slides: Corporate presentation
Cytokinetics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following ...
Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM
Cytokinetics (CYTK) announced that additional results from ACACIA-HCM and MAPLE-HCM were presented in a Late Breaking Clinical Session at the European Society of Cardiology, ESC, Congress 2026 in Muni...
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Met...
Cytokinetics Transcript: Investor update
ACACIA-HCM demonstrated that aficamten significantly improved exercise capacity, symptoms, and biomarkers in non-obstructive HCM, with a favorable safety profile and broad benefit across patient subgroups. The results support regulatory submission and may transform treatment for this underserved population.
Cytokinetics Press release: Investor update
Cytokinetics issued a press release on August 28, 2026, disclosing material business information to investors.
Cytokinetics reports ACACIA-HCM trial met both primary endpoints
Cytokinetics (CYTK) announced the primary results from ACACIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy were presented in a ...
Cytokinetics eyes expanded use of heart drug after promising late-stage data
Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no...
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM S...
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27...
Cytokinetics price target raised to $110 from $95 at Barclays
Barclays raised the firm’s price target on Cytokinetics (CYTK) to $110 from $95 and keeps an Overweight rating on the shares. The firm upped the company’s estimates citing its solid…
Cytokinetics price target raised to $103 from $97 at JPMorgan
JPMorgan raised the firm’s price target on Cytokinetics (CYTK) to $103 from $97 and keeps an Overweight rating on the shares. The firm upped its near-term estimates for Myqorzo. Published…
Cytokinetics price target raised to $112 from $106 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Cytokinetics (CYTK) to $112 from $106 and keeps a Buy rating on the shares as part of a broader research…
Cytokinetics price target raised to $85 from $83 at BofA
BofA raised the firm’s price target on Cytokinetics (CYTK) to $85 from $83 and keeps a Neutral rating on the shares. The company’s Q2 print was positive, given solid Myqorzo…
Cytokinetics price target raised to $112 from $102 at Needham
Needham analyst Serge Belanger raised the firm’s price target on Cytokinetics (CYTK) to $112 from $102 and keeps a Buy rating on the shares. The firm cites increased Myqorzo estimates…
Cytokinetics price target lowered to $112 from $117 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Cytokinetics (CYTK) to $112 from $117 and keeps an Outperform rating on the shares.
Cytokinetics price target raised to $110 from $105 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Cytokinetics (CYTK) to $110 from $105 and keeps an Outperform rating on the shares. Cytokinetics reported a strong Q2 with…
Cytokinetics Earnings Call Transcript: Q2 2026
MYQORZO's U.S. and European launches drove strong commercial momentum, with over 1,500 patients dispensed in Q2 and >40% new-to-brand share. Positive phase III results for aficamten in nHCM support a Q4 sNDA submission, while a $760M public offering strengthened the balance sheet.
Cytokinetics Earnings release: Q2 2026
Cytokinetics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cytokinetics Quarterly report: Q2 2026
Cytokinetics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cytokinetics reports Q2 EPS ($1.50), consensus ($1.60)
Reports Q2 revenue $28.62M, consensus $17.46M. “Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for our development pipeline, both hallmark...